Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupus Market Snapshot: There's No Debate It's A Blockbuster Opportunity

Executive Summary

Several drug makers are working to bring the next treatment for lupus to market, and the level of interest across the industry suggests the therapeutic area represents a big commercial opportunity.

You may also be interested in...



GSK Plans Benlysta Expansion In Lupus Nephritis Based On Successful Phase III

Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.

Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset

While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.

Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus

Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel